Physician profile
Daniel Arkfeld
NPI 1780610105
$377,543.03
in general payments reported to CMS, 2019-2025
24 companies · $57K in 2025
The $57K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $49K · 2021: $31K · 2022: $16K · 2023: $36K · 2024: $58K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Consulting Fee: $13K · Travel and Lodging: $11K · Food and Beverage: $9,844 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,961.00 |
| Consulting Fee | $13,166.50 |
| Travel and Lodging | $10,987.60 |
| Food and Beverage | $9,843.75 |
| Education | $238.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $163,410.07 | 2019-2025 | Tavneos, Uplizna, Evenity |
| Genzyme Corporation | $80,694.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $50,543.22 | 2020-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $34,081.69 | 2019-2022 | |
| Gilead Sciences, INC. | $15,570.34 | 2019 | |
| Abbvie INC. | $8,640.11 | 2019-2025 | Rinvoq, Skyrizi |
| Genentech USA, INC. | $5,790.23 | 2019-2025 | Gazyva, Actemra |
| Regeneron Healthcare Solutions, INC. | $4,310.37 | 2019 | |
| Janssen Biotech, INC. | $4,103.73 | 2022-2025 | Tremfya, Simponi Aria |
| Kyowa Kirin, INC. | $3,275.28 | 2025 | |
| Aurinia Pharma U.S., INC. | $2,548.84 | 2022-2024 | Lupkynis |
| Ucb, INC. | $2,065.61 | 2020-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $706.30 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $540.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $341.68 | 2021-2025 | Saphnelo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $217.84 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $152.20 | 2023-2025 | Strensiq, Ultomiris |
| Inspire Medical Systems, INC. | $125.00 | 2024 | Inspire |
| Mallinckrodt Enterprises LLC | $115.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $111.19 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $84.69 | 2023 | Uplizna |
| Fresenius Kabi USA, LLC | $77.03 | 2023-2024 | Idacio |
| Kiniksa Pharmaceuticals, Ltd. | $21.56 | 2021 | |
| Janssen Scientific Affairs, LLC | $16.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arkfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.